Hester Biosciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 8:16 am

Competitors of Hester Biosciences Ltd

All Competitor Stocks of Hester Biosciences Ltd

Quarterly Result

Last Updated: August 1, 2025, 8:05 pm

Below is a detailed analysis of the quarterly data for Hester Biosciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 2.00 Cr..
• For Expenses, as of Jun 2025, the value is 61.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 61.00 Cr., marking a decrease of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 4.00 Cr..
• For OPM %, as of Jun 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 27.00%, marking an increase of 4.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -6.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 9.00 Cr..
• For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 16.00 Cr..
• For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be improving (decreasing) as expected. It has decreased from 59.00% (Mar 2025) to 14.00%, marking a decrease of 45.00%.
• For Net Profit, as of Jun 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 15.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 19.33. The value appears strong and on an upward trend. It has increased from 1.52 (Mar 2025) to 19.33, marking an increase of 17.81.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:15 am

Growth

Last Updated: September 5, 2025, 6:05 am

Balance Sheet

Last Updated: July 25, 2025, 3:06 pm

Below is a detailed analysis of the balance sheet data for Hester Biosciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
• For Reserves, as of Mar 2025, the value is 306.00 Cr.. The value appears strong and on an upward trend. It has increased from 283.00 Cr. (Mar 2024) to 306.00 Cr., marking an increase of 23.00 Cr..
• For Borrowings, as of Mar 2025, the value is 213.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 244.00 Cr. (Mar 2024) to 213.00 Cr., marking a decrease of 31.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 126.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 126.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 653.00 Cr.. The value appears to be improving (decreasing). It has decreased from 662.00 Cr. (Mar 2024) to 653.00 Cr., marking a decrease of 9.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 233.00 Cr.. The value appears to be declining and may need further review. It has decreased from 240.00 Cr. (Mar 2024) to 233.00 Cr., marking a decrease of 7.00 Cr..
• For CWIP, as of Mar 2025, the value is 183.00 Cr.. The value appears strong and on an upward trend. It has increased from 171.00 Cr. (Mar 2024) to 183.00 Cr., marking an increase of 12.00 Cr..
• For Investments, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 4.00 Cr..
• For Other Assets, as of Mar 2025, the value is 203.00 Cr.. The value appears to be declining and may need further review. It has decreased from 221.00 Cr. (Mar 2024) to 203.00 Cr., marking a decrease of 18.00 Cr..
• For Total Assets, as of Mar 2025, the value is 653.00 Cr.. The value appears to be declining and may need further review. It has decreased from 662.00 Cr. (Mar 2024) to 653.00 Cr., marking a decrease of 9.00 Cr..

Notably, the Reserves (306.00 Cr.) exceed the Borrowings (213.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Hester Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
• For Diluted EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
• For Cash EPS (Rs.), as of Mar 25, the value is 48.82. This value is within the healthy range. It has increased from 39.65 (Mar 24) to 48.82, marking an increase of 9.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 365.70. It has increased from 357.99 (Mar 24) to 365.70, marking an increase of 7.71.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 76.38. This value is within the healthy range. It has increased from 75.58 (Mar 24) to 76.38, marking an increase of 0.80.
• For PBIT / Share (Rs.), as of Mar 25, the value is 56.63. This value is within the healthy range. It has increased from 55.39 (Mar 24) to 56.63, marking an increase of 1.24.
• For PBT / Share (Rs.), as of Mar 25, the value is 41.70. This value is within the healthy range. It has increased from 32.14 (Mar 24) to 41.70, marking an increase of 9.56.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 29.07. This value is within the healthy range. It has increased from 19.46 (Mar 24) to 29.07, marking an increase of 9.61.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.31. This value is within the healthy range. It has increased from 22.20 (Mar 24) to 32.31, marking an increase of 10.11.
• For PBDIT Margin (%), as of Mar 25, the value is 20.88. This value is within the healthy range. It has decreased from 21.11 (Mar 24) to 20.88, marking a decrease of 0.23.
• For PBIT Margin (%), as of Mar 25, the value is 15.48. This value is within the healthy range. It has increased from 15.47 (Mar 24) to 15.48, marking an increase of 0.01.
• For PBT Margin (%), as of Mar 25, the value is 11.40. This value is within the healthy range. It has increased from 8.97 (Mar 24) to 11.40, marking an increase of 2.43.
• For Net Profit Margin (%), as of Mar 25, the value is 7.94. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 7.94, marking an increase of 2.51.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.20 (Mar 24) to 8.83, marking an increase of 2.63.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.74. This value is below the healthy minimum of 15. It has increased from 6.47 (Mar 24) to 8.74, marking an increase of 2.27.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.12. This value is below the healthy minimum of 10. It has increased from 8.46 (Mar 24) to 9.12, marking an increase of 0.66.
• For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has increased from 2.85 (Mar 24) to 4.20, marking an increase of 1.35.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.66, marking a decrease of 0.15.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.47. It has increased from 0.45 (Mar 24) to 0.47, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.56, marking a decrease of 0.47.
• For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.99, marking a decrease of 0.32.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.26. This value is within the healthy range. It has increased from 0.67 (Mar 24) to 4.26, marking an increase of 3.59.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.56. This value is below the healthy minimum of 20. It has decreased from 36.02 (Mar 24) to 18.56, marking a decrease of 17.46.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.52. This value is below the healthy minimum of 20. It has decreased from 18.86 (Mar 24) to 11.52, marking a decrease of 7.34.
• For Earning Retention Ratio (%), as of Mar 25, the value is 81.44. This value exceeds the healthy maximum of 70. It has increased from 63.98 (Mar 24) to 81.44, marking an increase of 17.46.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.48. This value exceeds the healthy maximum of 70. It has increased from 81.14 (Mar 24) to 88.48, marking an increase of 7.34.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 5.12, marking an increase of 1.87.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.95, marking an increase of 1.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,279.65. It has decreased from 1,416.65 (Mar 24) to 1,279.65, marking a decrease of 137.00.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.11. This value exceeds the healthy maximum of 3. It has decreased from 4.65 (Mar 24) to 4.11, marking a decrease of 0.54.
• For EV / EBITDA (X), as of Mar 25, the value is 19.69. This value exceeds the healthy maximum of 15. It has decreased from 22.03 (Mar 24) to 19.69, marking a decrease of 2.34.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
• For Retention Ratios (%), as of Mar 25, the value is 81.43. This value exceeds the healthy maximum of 70. It has increased from 63.97 (Mar 24) to 81.43, marking an increase of 17.46.
• For Price / BV (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.39, marking a decrease of 0.66.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness